(1S,2R)-2-(2-propenyl)cyclopentanol | 145166-23-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1S,2R)-2-(2-propenyl)cyclopentanol
• 英文别名: (1S,2R)-2-prop-2-enylcyclopentan-1-ol
• CAS: 145166-23-0
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: AKMQRQYIMCRNHP-YUMQZZPRSA-N

物化性质

• 沸点：
  182.8±9.0 °C(Predicted)
• 密度：
  0.935±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1S,2R)-2-(2-propenyl)cyclopentanol 以61%的产率得到
  参考文献：
  名称：

  Curran Dennis P., Liu Hongtao, J. Chem. Soc. Perkin Trans. 1, (1994) N 11, S 1377-1393

  摘要：

  DOI：
• 作为产物：
  描述：

  氯丙烯镁 、 1,2-环氧环戊烷 以95%的产率得到
  参考文献：
  名称：

  HEGEDUS, L. S.;MCKEARIN, J. M., J. AMER. CHEM. SOC., 1982, 104, N 9, 2444-2451

  摘要：

  DOI：

文献信息

• A Facile Access to (<i>R</i>)-Methyl 2-Oxocyclopentane-1-acetate<i>via</i>Lipase-Catalyzed Irreversible Transesterification
  作者：Shun-ichi Hashimoto、Yoji Miyazaki、Shiro Ikegami

  DOI：10.1080/00397919208021673

  日期：1992.9

  Abstract A highly efficient kinetic resolution of (±)-methyl trans-2-hydroxycyclopentane-1-acetate via lipase PS-catalyzed irreversible transesterification provides a facile and economical entry to (R)-methyl 2-oxocyclopentane-1-acetate of 96% ee, a starting material for the convergent synthesis of (+)-isocarbacyclin.

  摘要 通过脂肪酶 PS 催化的不可逆酯交换对 (±)-甲基反式-2-羟基环戊烷-1-乙酸酯进行高效的动力学拆分，为 (R)-甲基 2-氧代环戊烷-1-乙酸酯提供了 96% 的简便且经济的进入ee，(+)-异碳环素收敛合成的起始材料。
• Intramolecular Photocycloaddition ofN-Alkenyl Substituted Maleimides: A Potential Tool for the Rapid Construction of Perhydroazaazulene Alkaloids
  作者：Kevin I. Booker-Milburn、Christopher E. Anson、Cole Clissold、Nicola J. Costin、Richard F. Dainty、Martin Murray、Dhiren Patel、Andrew Sharpe

  DOI：10.1002/1099-0690(200104)2001:8<1473::aid-ejoc1473>3.0.co;2-w

  日期：2001.4

  to high stereoselectivity being observed for 13e and 13g, respectively. Use of cyclic alkene side chains led to the formation of tri- and tetracyclic products with high degrees of stereoselectivity in most cases. Some of the polycyclic ring systems that were prepared constitute the core skeleton of a number of complex alkaloids. The substrate 29 underwent an unexpected [2+2] photocycloaddition to yield

  许多 N-链烯基取代的马来酰亚胺衍生物的紫外线照射导致以极好的产率形成复杂的全氢氮杂茚。整个过程可以被认为是一个正式的分子内 [5+2] 环加成。通过合适的烯醇与各种马来酰亚胺的Mitsunobu偶联制备底物。烯基侧链的甲基取代以良好的产率得到环加合物 13a-g，分别对 13e 和 13g 观察到中等至高的立体选择性。在大多数情况下，环状烯烃侧链的使用导致形成具有高度立体选择性的三环和四环产物。一些已制备的多环系统构成了许多复杂生物碱的核心骨架。
• 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE
  申请人：Evans Gary Brian

  公开号：US20120157479A1

  公开（公告）日：2012-06-21

  The present invention relates to 3-hydroxypyrrolidine compounds of the general formula (I) which are inhibitors of 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase. The invention also relates to the use of these compounds in the treatment of diseases or conditions in which it is desirable to inhibit 5′-methylthioadenosine phosphorylase or 5′-methylthioadenosine nucleosidase including cancer, and to pharmaceutical compositions containing the compounds.

  本发明涉及一般式(I)的3-羟基吡咯烷化合物，其为5'-甲基硫腺苷磷酸化酶或5'-甲基硫腺苷核苷酸酶的抑制剂。本发明还涉及使用这些化合物治疗需要抑制5'-甲基硫腺苷磷酸化酶或5'-甲基硫腺苷核苷酸酶的疾病或情况，包括癌症，并涉及含有这些化合物的药物组合物。
• ANTIBACTERIAL FLUOROQUINOLONE ANALOGS
  申请人：Wagman Allan S.

  公开号：US20120058989A1

  公开（公告）日：2012-03-08

  Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein A, B, D, E, G, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明公开了具有抗菌活性的化合物。该化合物具有以下结构（I）：包括立体异构体、药学上可接受的盐和前药，其中A、B、D、E、G、R1、R2、R3、R4、R5、R6和R7如本文所定义。本发明还公开了与制备和使用这种化合物相关的方法，以及包含这种化合物的制药组合物。
• COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
  申请人：AMGEN INC.

  公开号：US20210230189A1

  公开（公告）日：2021-07-29

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.